Innate Pharma doses first patient in Sanofi-sponsored SAR’514 / IPH6401 trial

Innate Pharma (IPHA) announced that the first patient was dosed in a Sanofi-sponsored (SNY) Phase 1/2 clinical trial, evaluating SAR’514 / IPH6401 in relapsed/refractory Multiple Myeloma and Relapsed/Refractory Light-chain Amyloidosis. SAR’514 is a trifunctional anti-BCMA NKp46xCD16 NK cell engager, using Sanofi’s proprietary Crossodile multi-functional platform, which comprises the Cross-Over-Dual-Variable-Domain, or CODV, format. It induces a dual targeting of the NK activating receptors, NKp46 and CD16, for an optimized NK cell activation, based on Innate’s Anket proprietary platform. The purpose of the dose escalation and dose expansion study is to evaluate the safety, pharmacokinetics and preliminary efficacy of SAR’514 in monotherapy in patients with RRMM and RRLCA.